Bluejay Diagnostics, Inc. cash flow statement

In fiscal 2022, Bluejay Diagnostics, Inc.'s operations generated −$7.7m of cash; it spent $1.2m on capital projects, leaving free cash flow of −$8.9m.

Cash flow statement

US$ thousands unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Bluejay Diagnostics, Inc.: cash flow statement, annual
Fiscal year	2022Dec 2022
Cash from operations	−7,742
Depreciation and amortisation	157
Stock-based pay	433
Capital spending	1,199
Free cash flow	−8,941
Free cash flow after stock pay	−9,374

US$ thousands unless shown otherwise. Fiscal quarters.

Bluejay Diagnostics, Inc.: cash flow statement, quarterly
Quarter	2022 Q2Jun 2022	2022 Q3Sept 2022	2022 Q4Dec 2022
Cash from operations	−1,659	−1,261	−2,944
Depreciation and amortisation	44	42	31
Stock-based pay	106	113	88
Capital spending	123	791	238
Free cash flow	−1,782	−2,052	−3,182
Free cash flow after stock pay	−1,888	−2,166	−3,270

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

More: Health Care Equipment stocks compared, Health Care sector, rankings of US companies

Figures from Bluejay Diagnostics, Inc.'s SEC filings (10-K and 10-Q), retrieved October 31, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Bluejay Diagnostics, Inc.